Zongertinib

Definition

An orally bioavailable inhibitor of the receptor tyrosine kinase human epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), with potential antineoplastic activity. Upon oral administration, zongertinib covalently binds to and inhibits the activity of both wild-type and HER2 mutants, including HER2 mutants with exon 20 insertion (ex20ins) mutations. This prevents HER2-mediated signaling and may lead to cell death in HER2-expressing tumor cells. HER2, a receptor tyrosine kinase overexpressed on a variety of tumor cell types, plays an important role in tumor cell proliferation and tumor vascularization.

Also known as BI 1810631, BI-1810631, BI1810631, HER-2 Inhibitor BI 1810631, HER2 Inhibitor BI 1810631, Hernexeos, ZONGERTINIB — per NCIT

Also identified as

• ATC L01EH04 per RXNORM
• NCIT NCIT:C199022 per NCIT
• UNII DRH7R67UVL per RXNORM

Indications

Organ Effects

1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.